Literature DB >> 26795391

[Cardiotoxicity of trastuzumab in the adjuvant treatment of breast cancer patients : Results of the NCCTG N9831 trial].

David Krug1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26795391     DOI： 10.1007/s00066-015-0938-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.

Authors:  Lucas Caussa; Youlia M Kirova; Nathalie Gault; Jean-Yves Pierga; Alexia Savignoni; François Campana; Rémi Dendale; Alain Fourquet; Marc A Bollet
Journal:  Eur J Cancer       Date:  2010-09-16       Impact factor: 9.162

2.  Trastuzumab-related cardiotoxicity among older patients with breast cancer.

Authors:  Mariana Chavez-MacGregor; Ning Zhang; Thomas A Buchholz; Yufeng Zhang; Jiangong Niu; Linda Elting; Benjamin D Smith; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

4.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.

Authors:  Pooja P Advani; Karla V Ballman; Travis J Dockter; Gerardo Colon-Otero; Edith A Perez
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

Review 5.  Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.

Authors:  Tao Chen; Tao Xu; Yang Li; Chun Liang; Juxiang Chen; Yicheng Lu; Zonggui Wu; Shenhong Wu
Journal:  Cancer Treat Rev       Date:  2010-10-16       Impact factor: 12.111

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

8.  Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

Authors:  Michele Y Halyard; Thomas M Pisansky; Amylou C Dueck; Vera Suman; Lori Pierce; Larry Solin; Larry Marks; Nancy Davidson; Silvana Martino; Peter Kaufman; Leila Kutteh; Shaker R Dakhil; Edith A Perez
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

Review 9.  Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Authors:  Melinda L Telli; Sharon A Hunt; Robert W Carlson; Alice E Guardino
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

10.  Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Authors:  Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner
Journal:  J Natl Cancer Inst       Date:  2012-09-05       Impact factor: 13.506
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.